Primary oral etoposide therapy in gestational trophoblastic disease: An update

68Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sixty patients who developed persistent or metastatic gestational trophoblastic disease (GTD) received primary oral etoposide therapy (VP 16–213). Twelve patients had metastatic GTD. Fifty‐nine patients achieved biochemical remission. One patient had marked nausea and vomiting and the therapy was switched to a methotrexate/folinic acid regimen. Three patients developed relapse of GTD, giving a relapse rate of 5.1%. Etoposide is an active drug against choriocarcinoma. Its use should not be restricted to drug‐resistant GTD. Cancer 58:14–17, 1986. Copyright © 1986 American Cancer Society

Cite

CITATION STYLE

APA

Wong, L. C., Choo, Y. C., & Ma, H. K. (1986). Primary oral etoposide therapy in gestational trophoblastic disease: An update. Cancer, 58(1), 14–17. https://doi.org/10.1002/1097-0142(19860701)58:1<14::AID-CNCR2820580104>3.0.CO;2-R

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free